Arachidonate.

Linoleic acid is desaturated by delta-6 desaturase to gamma-linolenic acid, elongated to dihomo-gamma-linolenic acid, then desaturated again by delta-5 desaturase to arachidonic acid. Conversion efficiency along that chain is low in humans and falls further when the same enzymes are occupied by omega-3 substrates. Direct arachidonate intake bypasses the rate-limiting desaturation steps.

Gamma-linolenic acid is elongated to dihomo-gamma-linolenic acid, which is both a direct substrate for series-1 eicosanoids and the immediate precursor that delta-5 desaturase converts to arachidonic acid. Supplying GLA therefore raises tissue dihomo-gamma-linolenic acid substantially and arachidonate only modestly, because the delta-5 step is constrained. The two sit on the same linear pathway with different accumulation behaviour.

Eicosapentaenoic acid competes with arachidonic acid for incorporation at the sn-2 position of membrane phospholipids and for access to cyclooxygenase and lipoxygenase. When EPA occupies those sites the eicosanoids formed belong to the series-3 and series-5 families rather than the series-2 and series-4 families derived from arachidonate. Raising one lowers the membrane share of the other, a displacement that is well documented in membrane lipid analysis.

Docosahexaenoic acid and arachidonic acid are the two dominant long-chain polyunsaturated fatty acids of brain and retinal phospholipids and are handled by overlapping acyltransferases. High-dose DHA lowers tissue arachidonate share, which is why infant formula standards specify the two together in a stated proportion. The relationship is reciprocal displacement rather than opposition.

Mixed EPA and DHA oils lower the arachidonate content of red cell and tissue phospholipids in a dose-dependent way. A formula carrying arachidonate alongside fish oil is setting a ratio rather than adding two independent inputs. Membrane fatty acid composition is a marker of that shift, not an outcome in itself.

Delta-6 and delta-5 desaturase activity falls when zinc is inadequate, which slows conversion of linoleic acid along the pathway toward arachidonic acid. That makes zinc status one determinant of how much arachidonate the body makes from dietary omega-6. It has no bearing on preformed arachidonate taken directly.

Pyridoxal 5-phosphate is among the cofactors required for normal desaturase and elongase function in the omega-6 conversion sequence. Its role sits upstream of arachidonate formation from dietary linoleic acid. As with zinc, it does not affect preformed arachidonate.

Arachidonic acid carries four methylene-interrupted double bonds, so its bis-allylic hydrogens abstract readily and it propagates lipid peroxidation chains quickly. Alpha-tocopherol sits in the membrane and terminates those chains, which is why arachidonate oils are formulated with tocopherol. The pairing protects the material as well as the membrane it enters.

Astaxanthin spans the lipid bilayer with its polar end groups at both membrane surfaces, which lets it intercept radicals at the interface as well as within the core. Highly unsaturated fatty acids such as arachidonate are the substrates most vulnerable there. The rationale is positional chemistry rather than a measured combination effect.

Arachidonic acid does not circulate free to any meaningful degree; it is stored esterified at the sn-2 position of membrane phospholipids and released on demand by phospholipase A2. Phosphatidylcholine supplies the backbone for that storage pool and for the Lands cycle remodelling that loads it. Supplying phospholipid alongside the fatty acid is a delivery choice with a mechanistic basis.

Lecithin emulsifies the oil into finer droplets, which increases the surface available to pancreatic lipase and to bile salt micelles. Long-chain fatty acids absorbed this way are re-esterified into chylomicrons in the enterocyte. This is delivery chemistry and says nothing about what the fatty acid does afterwards.

Curcumin is reported to inhibit cyclooxygenase-2 expression and 5-lipoxygenase activity, the two enzymes that convert released arachidonate into eicosanoids. Combining the two therefore raises substrate while damping its conversion, which is a genuine interaction rather than an additive one. Most of the supporting work is in vitro or in animals.

Boswellic acids act on 5-lipoxygenase, the enzyme that converts released arachidonic acid to the leukotriene family. Any arachidonate supplied enters that same substrate pool. The interaction is at the enzyme, and the human evidence for the modulating partner is thinner than the in vitro work.

Gingerols and shogaols are described as acting on both branches of arachidonate conversion in laboratory systems. That places them directly downstream of any supplied arachidonate. Read it as mechanistic rather than clinical.

Quercetin has been reported to inhibit lipoxygenase activity in cell-free and cell-based systems, which is one of the two routes released arachidonate takes. The concentrations used in those systems often exceed what oral intake achieves in plasma. The pairing is worth flagging as an interaction, not as an effect.

Cytosolic phospholipase A2 activity depends on divalent cations for membrane translocation and catalysis, and the acyl-CoA synthetases that activate fatty acids for re-esterification require magnesium-ATP. Both steps sit in the release and recycling loop for membrane arachidonate. This is background enzymology rather than a supplement pairing with a measured result.

Arachidonic acid appears in some resistance-training products alongside protein, on the reasoning that one supplies substrate for membrane signalling lipids and the other supplies amino acids for tissue protein. The two act by unrelated routes. This is formulation convention and not a tested combination.